Whitehawk Therapeutics, Inc. (WHWK)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Whitehawk Therapeutics, Inc..
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 9 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 4.00 $ — 69% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
1/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 45.6%
- Exp. sales growth 3Y > 5% –
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% –
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% -15.1%
- ROCE > 15% -83.9%
- Expected return > 10% –
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
4 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -22.3% failed
- More than 10% revenue growth is expected for the coming year 0.0% failed
- Share count grows by less than 3% a year 40.1% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -1,443.9% failed
- Gross margin at 40% or higher and without meaningful erosion 89.4% passed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 146 m net cash passed
- Operating cash flow covers the profits of the last three years -67 m failed
- Return on capital at 15% or higher, or up versus two years ago -83.9% failed
- Insiders hold at least 10% or are net buyers 13.4% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 87.5% above the current price.
- Consensus
- Hold
- Analyst Ratings
- 3
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -1.11 | -1.21 – -0.99 | -1 | 36.3% | 4 |
| 12/31/2027 | -1.10 | -1.26 – -0.95 | -1 | 0.7% | 4 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.30 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.37 | – | 7 | 14.40 | -252.40 | -15 | -15 |
| 2025: Q1 | 1.48 | – | 7 | 33.50 | 1,021.90 | -12 | -12 |
| 2025: Q2 | -1.06 | – | 0 | -100.00 | – | -53 | -53 |
| 2025: Q3 | -0.36 | – | 0 | -100.00 | – | -15 | -15 |
| 2025: Q4 | -0.47 | – | 0 | -100.00 | – | -17 | -17 |
| 2026: Q1 | -0.45 | -130.40 | 0 | -100.00 | – | -22 | -22 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2019 | 1 | -12 | -12 | -1.53 | -8 | -9 | 17 |
| 2020 | 15 | -3 | -3 | -0.20 | -13 | -12 | 19 |
| 2021 | 1 | -111 | -110 | -12.34 | -22 | 136 | 158 |
| 2022 | 15 | -63 | -61 | -2.69 | -50 | 158 | 184 |
| 2023 | 24 | -72 | -66 | -2.44 | -60 | 105 | 132 |
| 2024 | 26 | -67 | -64 | -2.36 | -60 | 52 | 70 |
| 2025 | 7 | -114 | -21 | -0.33 | -97 | 136 | 151 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Whitehawk Therapeutics, Inc. ist ein onkologisches Therapieunternehmen in der klinischen Phase, das Technologien zur Erfassung der Tumorbiologie für Krebsbehandlungen entwickelt.
| Employees | 29 |
|---|---|
| Headquarters | Morristown, NJ |
| Address | 2 Headquarters Plaza, 07960 Morristown, United States |
| Phone | 551 321 2234 |
| Website | ir.whitehawktx.com |
| IPO Date | 8. Aug 2017 |
| ISIN | US00032Q1040 |
| Stock Split | 1:15 on 08/27/2021 |
Management
| Name | Title | Birth Year |
|---|---|---|
| David J. Lennon Ph.D. | President, CEO & Director | 1971 |
| Neil P. Desai Ph.D. | Founder & Director | 1965 |
| Scott M. Giacobello CPA | CFO, Treasurer, Investor Relations & Corporate Communications | 1970 |
| Bryan Ball | Chief Technical Operations Officer | 1970 |
| David Dornan Ph.D. | Chief Scientific Officer | 1978 |
| Stephen M. Rodin J.D. | Senior VP of Legal & General Counsel | 1976 |
| Margaret Han Dugan M.D. | Chief Medical Officer | 1957 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 14. May 2026 | Dalal Anupam | Director | Other | 1,275,510 | 3.92 | 4,999,999 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.